AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00630370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ATI 7505
Description: 2 ATI 40mg tablets, TID, orally, 58 days
Study NCT03720353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS2094AH and SAS2094BH
Description: SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
Study NCT03720353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS2094AL and SAS2094BL
Description: SAS2094AL and SAS2094BL for 10 days
Study NCT03720353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 10 days. Capsules will mimic active treatments.
Study NCT01024335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injectable naltrexone and dronabinol
Description: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
Study NCT01024335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone and placebo
Description: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
Study NCT03144921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational skills training intervention
Description: This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
Study NCT03144921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducational skills training intervention
Description: This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
Study NCT00002561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate
Description: 10 units/m2
Study NCT04503369 — intervention group
Intervention type: BEHAVIORAL
Intervention: Non-technical skills
Description: Teamwork The work of the team consists of information exchange and coordination of all activities performed. In-team communication is always calm and assertive, and team members support each other.~Task management With the right planning and preparation of individual activities, the likelihood that all standards of care and best practices will be followed increases.~Situational awareness Situational awareness refers primarily to the collection of information, its understanding and, on that basis, prediction of direction into which the situation will develop. Maintaining situational awareness is crucial in order to move towards the right goal.~Decision-making With good situational awareness, one is able to keep in mind all information needed to make the correct decision at the right time. In some cases, it is advisable to consult with other team members or to verify their consent to the proposed procedure.~Communication Communication is a vital tool when working in a team.
Study NCT00149357 — intervention group
Intervention type: OTHER
Intervention: Thrombophilia Testing
Description: TP testing in Group 1 and 3 only
Study NCT02853292 — intervention group
Intervention type: BIOLOGICAL
Intervention: urine collection
Study NCT00685295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl rapid dissolving tablet 100mcg
Study NCT00685295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: lansoprazole 15mg rapidly dissolving tablet
Study NCT00685295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone 5/325 mg tablet
Study NCT04085250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Description: The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
Study NCT04085250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy
Description: The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
Study NCT04085250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy concurrent with radiotherapy
Description: Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)
Study NCT04085250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy concurrent with radiotherapy
Description: Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)
Study NCT04085250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hypofractionated radiation technique was used to deliver a definitive radiation dose
Study NCT04085250 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Hypofractionated radiation technique was used to deliver a definitive radiation dose
Study NCT04085250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab consolidation (360 mg) via iv infusion once every 3 weeks (Q3W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 12 months.
Study NCT04085250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
Study NCT03859011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion.
Study NCT03859011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion.
Study NCT03859011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
Study NCT03859011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
Study NCT03088683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nathanson Retractor
Description: Liver will be retracted with Nathanson retractor
Study NCT00638326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
Study NCT00638326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel plus placebo
Description: 75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
Study NCT03088683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveel Retractor
Description: Liver will be retracted with Reveel retractor
Study NCT00002561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: 375mg/m2
Study NCT00002561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 25mg/m2
Study NCT00002561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine
Description: 6mg/m2
Study NCT00002561 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 35Gy in 20 fractions (daily)
Study NCT04521816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT Intensive Management
Description: Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues
Study NCT00469378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: firategrast
Description: 900 (females) or 1200 (males) mg twice daily for 24 weeks
Study NCT00712166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI 75 mg three times daily (TID)
Study NCT00712166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo three times daily (TID)
Study NCT02661646 — intervention group
Intervention type: DEVICE
Intervention: Advanced Pneumatic Compression Device
Description: Advanced Pneumatic Compression Device
Study NCT00556062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal split influenza vaccine
Description: 0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
Study NCT00556062 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: seasonal split influenza vaccine
Description: 0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
Study NCT03947112 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical activity registration
Description: At start, participants and parents fills out a Self-report questionnaire and the UngKan-3 Questionnaire, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
Study NCT01264718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Mentors
Description: After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
Study NCT02908464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumosity
Description: A neurocognitive training program designed to enhance cognitive abilities
Study NCT03102242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.
Study NCT05464212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG Guided Greater Occipital Nerve Block
Description: With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
Study NCT05464212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency
Description: With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
Study NCT00598897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin, rifabutin
Description: Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
Study NCT04446689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph.
Study NCT02957292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (13,5 mg) intrauterine device
Study NCT02957292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cooper (380mm2) intrauterine device
Study NCT04376814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days
Study NCT04376814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
Study NCT04376814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
Study NCT04376814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
Study NCT01895517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LBC
Description: Cervical cancer screening by using liquid based cytology as a standard screening modality
Study NCT01895517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LBC plus HPV DNA testing
Description: Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
Study NCT03201614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-CP HA Kit
Description: Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2
Study NCT03201614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArthroVisc 40
Description: Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2
Study NCT03201614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
Study NCT00880490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT005
Description: single dose, inhaled
Study NCT00880490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: single dose, inhaled
Study NCT00880490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 mcg (Foradil Aerolizer)
Description: single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
Study NCT01769391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV
Study NCT01769391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study NCT02607969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home program
Description: Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
Study NCT00505687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours.
Study NCT04319809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Object recognition subsystem
Description: The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
Study NCT02341274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Bioequivalence study
Study NCT05035108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hiHep bioartificial liver therapy
Description: HiHep cell bioartificial liver treatment was performed 24-48 hours after extensive hepatectomy. Temporary hemodialysis tube for large vein (jugular vein or femoral vein) is indwelled before treatment. Before treatment, prepare hiHeps-BAL in a biological safety cabinet that meets clinical standards, connect the corresponding tubing to the Jianfan DX-10 blood purification machine, and prefill with heparin saline. Half an hour before treatment, the patient was pre-heparinized (heparin about 600iu) and dexamethasone to prevent allergic reactions. The patient enters the ICU, the monitor is connected to the corresponding pipeline, the arterial pump 120-160ml/min, the slurry pump 30-40ml/min, the circulating pump 75-100ml/min, the duration is 6-9h.
Study NCT02329808 — intervention group
Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
Study NCT02343237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: osteopathic sessions of 20 minutes
Study NCT02343237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Factitious osteopathic treatment
Description: 6 factitious osteopathic sessions of 20 minutes
Study NCT01128517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal education on complementary feeding
Description: CF education to the mothers in intervention arm.~* Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 \& 2006).~* First session --> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.~* Second session -->breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.~* Third session --> previous sessions recall. protein based and iron rich food encouragement.~* The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm
Study NCT01128517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Maternal education on complementary food
Study NCT03314584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
Study NCT03314584 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
Study NCT01769391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV